118 related articles for article (PubMed ID: 9648627)
1. Effects of receptor blockade on metabolism and renal actions of vasopressin in conscious dogs.
Grove L; Christensen P; Bie P
Acta Physiol Scand; 1998 May; 163(1):93-101. PubMed ID: 9648627
[TBL] [Abstract][Full Text] [Related]
2. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
[TBL] [Abstract][Full Text] [Related]
3. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
Naitoh M; Suzuki H; Murakami M; Matsumoto A; Ichihara A; Nakamoto H; Yamamura Y; Saruta T
Am J Physiol; 1993 Oct; 265(4 Pt 2):R934-42. PubMed ID: 8238468
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
[TBL] [Abstract][Full Text] [Related]
5. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
6. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
Oldziej S; Ciarkowski J; Liwo A; Shenderovich MD; Grzonka Z
J Recept Signal Transduct Res; 1995; 15(1-4):703-13. PubMed ID: 8903974
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.
Molnár AH; Varga C; Berkó A; Rojik I; Párducz A; László F; László FA
Acta Neurochir (Wien); 2008 Mar; 150(3):265-71. PubMed ID: 18288441
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.
Naitoh M; Suzuki H; Murakami M; Matsumoto A; Arakawa K; Ichihara A; Nakamoto H; Oka K; Yamamura Y; Saruta T
Am J Physiol; 1994 Dec; 267(6 Pt 2):H2245-54. PubMed ID: 7810724
[TBL] [Abstract][Full Text] [Related]
9. The effect of AVP-V2 receptor stimulation on local GFR in the rat kidney.
Roald AB; Tenstad O; Aukland K
Acta Physiol Scand; 2000 Feb; 168(2):351-9. PubMed ID: 10712572
[TBL] [Abstract][Full Text] [Related]
10. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs.
Brooks DP; Valente M; Petrone G; Depalma PD; Sbacchi M; Clarke GD
J Pharmacol Exp Ther; 1997 Mar; 280(3):1176-83. PubMed ID: 9067301
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of vasopressin natriuresis in the dog: role of vasopressin receptors and prostaglandins.
Kompanowska-Jezierska E; Emmeluth C; Grove L; Christensen P; Sadowski J; Bie P
Am J Physiol; 1998 Jun; 274(6):R1619-25. PubMed ID: 9608016
[TBL] [Abstract][Full Text] [Related]
14. Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in patients with non-insulin dependent diabetes mellitus.
Nishikawa T; Omura M; Iizuka T; Saito I; Yoshida S
Arzneimittelforschung; 1996 Sep; 46(9):875-8. PubMed ID: 8876935
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
[TBL] [Abstract][Full Text] [Related]
16. Blocking effects of OPC-21268 and OPC-31260 (vasopressin V1- and V2-receptor antagonists) on vasopressin-induced constrictions in isolated, perfused dog femoral arteries.
Chiba S; Tsukada M
Jpn J Pharmacol; 1992 May; 59(1):133-5. PubMed ID: 1324373
[TBL] [Abstract][Full Text] [Related]
17. Effect of vasopressin V (OPC-21268) and V2 (OPC-31260) antagonists on renal hemodynamics and excretory function.
Nakamura T; Sakamaki T; Kurashina T; Hoshino J; Sato K; Ono Z; Murata K
Life Sci; 1994; 55(4):PL67-72. PubMed ID: 8028441
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin receptor subtypes on mesenteric and cremasteric arterioles in rat.
Ishiguro S; Iwasaki T; Miyamoto A; Mori T; Nishio A
Eur J Pharmacol; 2000 Jul; 400(1):121-5. PubMed ID: 10913593
[TBL] [Abstract][Full Text] [Related]
19. Organic osmolytes in rat renal inner medulla are modulated by vasopressin V1 and/or V2 antagonists.
Nakanishi T; Yamauchi A; Nakahama H; Yamamura Y; Yamada Y; Orita Y; Fujiwara Y; Uyeda N; Takamitsu Y; Sugita M
Am J Physiol; 1994 Jul; 267(1 Pt 2):F146-52. PubMed ID: 8048555
[TBL] [Abstract][Full Text] [Related]
20. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists.
Bax WA; Van der Graaf PH; Stam WB; Bos E; Nisato D; Saxena PR
Eur J Pharmacol; 1995 Oct; 285(2):199-202. PubMed ID: 8566139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
